FDA Accepts Supplement for CARDIOGEN-82 by BRACCO
The FDA has accepted a supplemental application for CARDIOGEN-82, a radiopharmaceutical used in cardiac imaging.
Company
Pharmaceutical intelligence for CARDIOGEN-82 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.